Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
UroGen Pharma Ltd. logo

NASDAQ · URGN

UroGen Pharma Ltd.

Healthcare · Biotechnology

$34.40

Up+$0.04 (+0.12%)

Updated Nov 4, 2026, 5:32 AM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.05B
P/E ratio
-6.89
Dividend yield
0.00%
52-week range
$16.50 – $50.81
Volume
1.24M
Avg. volume
1.14M

Price performance · URGN

URGN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

URGN closed at $34.40 after 21 trading sessions, down 16.97% for the selected period.

Last close
$34.40
Period change
-16.97%
Period low
$32.72
Period high
$41.43
Daily close
View OHLC price history
URGN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$34.50$34.97$34.00$34.401.24M
Nov 2, 2026$32.95$34.88$32.45$34.362.04M
Oct 30, 2026$33.14$33.6463$32.39$32.721.17M
Oct 29, 2026$33.79$34.94$32.96$33.481.44M
Oct 28, 2026$33.66$34.04$33.10$33.751.59M
Oct 27, 2026$34.16$34.50$33.50$33.911.03M
Oct 26, 2026$34.64$35.00$33.87$34.04670.05K
Oct 23, 2026$34.44$35.02$33.80$34.49738.1K
Oct 22, 2026$35.23$35.98$34.11$35.15689.1K
Oct 21, 2026$35.25$36.46$35.05$35.48776.97K
Oct 20, 2026$34.05$35.695$34.00$35.01747.76K
Oct 19, 2026$34.75$35.4827$33.40$34.151.27M
Oct 16, 2026$36.35$36.91$34.26$34.561.06M
Oct 15, 2026$37.04$38.37$36.27$36.61636.57K
Oct 14, 2026$37.96$39.09$36.44$36.581.08M
Oct 13, 2026$37.82$38.84$37.30$38.26759.91K
Oct 12, 2026$36.97$38.315$36.20$38.28531K
Oct 9, 2026$36.97$38.11$36.685$36.833.9M
Oct 8, 2026$39.93$40.05$34.18$36.982.02M
Oct 7, 2026$40.70$41.93$40.64$40.70486.48K
Oct 6, 2026$43.24$43.54$41.095$41.43764.45K

Latest URGN news

The latest Smart Investors Daily articles mentioning URGN.

Stock researchCompany · Overview

URGN research

Overview

Company profile and research snapshot.

Company profile

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$23.50
Implied upside
—
Analysts
14
URGN recent ratings
DateFirmRatingTarget
Oct 19, 2026HC Wainwright & Co.Buy—
Aug 6, 2026GuggenheimBuy—
Aug 6, 2026HC Wainwright & Co.Buy—
Aug 5, 2026TD CowenBuy—
Jul 21, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026

Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ETPRINCETON, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2026 financial results on Wednesday, November 4th, 2026, prior to the open of the stock market. The announcement will be followed by a live audio web

Yahoo · Oct 20, 2026

Why UroGen Pharma (URGN) Is Getting Fresh Attention Now

UroGen Pharma (URGN) just hit a key regulatory milestone. The FDA accepted its New Drug Application for UGN-103 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, with a PDUFA decision date set for June 14, 2027. The FDA update lands after a choppy stretch for UroGen Pharma’s share price, which is down 21.0% over the past month and 22.0% over the last 90 days. Even so, the year-to-date share price return is 50.4% and the 1-year total shareholder return is 89.8%,...

Yahoo · Oct 19, 2026

UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for investigational drug UGN-103 (mitomycin) for intravesical solution for the treatment of adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-N

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By